Loading…
Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study
BACKGROUND: Endothelial dysfunction is probably one of the mechanisms of long COVID-19 symptoms. Sulodexide has pleiotropic properties within the vascular endothelium that can prove beneficial in the long COVID-19 symptoms. PURPOSE: We aimed to evaluate the effect of sulodexide when used in patients...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Online Article Text |
Language: | English |
Published: |
Published by Elsevier Masson SAS
2022
|
Subjects: | |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710949/ http://dx.doi.org/10.1016/j.acvdsp.2021.10.007 |
_version_ | 1784623274659938304 |
---|---|
author | Charfeddine, S. Ibn Hadjamor, H. Torjmen, S. Kraiem, S. Hammami, R. Bahloul, A. Kallel, N. Moussa, N. Touil, I. Jdidi, J. Abdesselem, S. Abid, L. |
author_facet | Charfeddine, S. Ibn Hadjamor, H. Torjmen, S. Kraiem, S. Hammami, R. Bahloul, A. Kallel, N. Moussa, N. Touil, I. Jdidi, J. Abdesselem, S. Abid, L. |
author_sort | Charfeddine, S. |
collection | PubMed |
description | BACKGROUND: Endothelial dysfunction is probably one of the mechanisms of long COVID-19 symptoms. Sulodexide has pleiotropic properties within the vascular endothelium that can prove beneficial in the long COVID-19 symptoms. PURPOSE: We aimed to evaluate the effect of sulodexide when used in patients with endothelial dysfunction and long COVID-19 symptoms. METHODS: We conducted a prospective multicenter longitudinal case-control study. Endothelial function was evaluated with DTM “E4-Diagnose” Polymath based on the Endothelium Quality Index (EQI). A group of patients with endothelial dysfunction (EQI < 2.0) received sulodexide. All the patients were followed-up 21 days after inclusion. Primary outcomes were defined as endothelial function amelioration (delta EQI) and long COVID-19 symptoms evolution during the follow-up. RESULTS: A total of 410 patients were included in this study. Patients were included at an average time of 1.89 ± 1.2 month after COVID-19 infection. At inclusion, 210 (51.2%) patients had an EQI < 2. The median age was 49 ± 13.8 (18–80) years. Among the patients with endothelial dysfunction, only 79 patients received sulodexide. Patients in sulodexide group had lower EQI than the non-medical intervention group (0.94 ± 0.6 vs. 1.52 ± 0.4; P < 10(−3)). They were more diabetic, hypertensive, had more coronary artery disease and received more long-term medications (aspirin, Bblockers and statins) than the others (P = 0.01, 0.002, 0.01, 0.009, 0.001 and 0.01, respectively). At the 21-days follow-up, patients in sulodexide group presented lower long COVID symptoms especially chest pain, palpitations, fatigue and neuro-cognitive difficulties associated to a significant amelioration of endothelial function (delta EQI 1.26 ± 1.07 vs. 0.22 ± 0.7; P < 10(−3)). CONCLUSION: Sulodexide in patients with long COVID-19 may be a good intervention to ameliorate chest pain, palpitations, fatigue and neuro-cognitive difficulties associated to endothelial dysfunction. |
format | Online Article Text |
id | pubmed-8710949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Masson SAS |
record_format | MEDLINE/PubMed |
spelling | pubmed-87109492021-12-28 Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study Charfeddine, S. Ibn Hadjamor, H. Torjmen, S. Kraiem, S. Hammami, R. Bahloul, A. Kallel, N. Moussa, N. Touil, I. Jdidi, J. Abdesselem, S. Abid, L. Archives of Cardiovascular Diseases. Supplements 329 BACKGROUND: Endothelial dysfunction is probably one of the mechanisms of long COVID-19 symptoms. Sulodexide has pleiotropic properties within the vascular endothelium that can prove beneficial in the long COVID-19 symptoms. PURPOSE: We aimed to evaluate the effect of sulodexide when used in patients with endothelial dysfunction and long COVID-19 symptoms. METHODS: We conducted a prospective multicenter longitudinal case-control study. Endothelial function was evaluated with DTM “E4-Diagnose” Polymath based on the Endothelium Quality Index (EQI). A group of patients with endothelial dysfunction (EQI < 2.0) received sulodexide. All the patients were followed-up 21 days after inclusion. Primary outcomes were defined as endothelial function amelioration (delta EQI) and long COVID-19 symptoms evolution during the follow-up. RESULTS: A total of 410 patients were included in this study. Patients were included at an average time of 1.89 ± 1.2 month after COVID-19 infection. At inclusion, 210 (51.2%) patients had an EQI < 2. The median age was 49 ± 13.8 (18–80) years. Among the patients with endothelial dysfunction, only 79 patients received sulodexide. Patients in sulodexide group had lower EQI than the non-medical intervention group (0.94 ± 0.6 vs. 1.52 ± 0.4; P < 10(−3)). They were more diabetic, hypertensive, had more coronary artery disease and received more long-term medications (aspirin, Bblockers and statins) than the others (P = 0.01, 0.002, 0.01, 0.009, 0.001 and 0.01, respectively). At the 21-days follow-up, patients in sulodexide group presented lower long COVID symptoms especially chest pain, palpitations, fatigue and neuro-cognitive difficulties associated to a significant amelioration of endothelial function (delta EQI 1.26 ± 1.07 vs. 0.22 ± 0.7; P < 10(−3)). CONCLUSION: Sulodexide in patients with long COVID-19 may be a good intervention to ameliorate chest pain, palpitations, fatigue and neuro-cognitive difficulties associated to endothelial dysfunction. Published by Elsevier Masson SAS 2022-01 2021-12-27 /pmc/articles/PMC8710949/ http://dx.doi.org/10.1016/j.acvdsp.2021.10.007 Text en Copyright © 2021 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | 329 Charfeddine, S. Ibn Hadjamor, H. Torjmen, S. Kraiem, S. Hammami, R. Bahloul, A. Kallel, N. Moussa, N. Touil, I. Jdidi, J. Abdesselem, S. Abid, L. Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study |
title | Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study |
title_full | Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study |
title_fullStr | Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study |
title_full_unstemmed | Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study |
title_short | Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: The results of TUN-EndCOV study |
title_sort | sulodexide in the treatment of patients with long covid 19 symptoms and endothelial dysfunction: the results of tun-endcov study |
topic | 329 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710949/ http://dx.doi.org/10.1016/j.acvdsp.2021.10.007 |
work_keys_str_mv | AT charfeddines sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT ibnhadjamorh sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT torjmens sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT kraiems sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT hammamir sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT bahloula sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT kalleln sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT moussan sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT touili sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT jdidij sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT abdesselems sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy AT abidl sulodexideinthetreatmentofpatientswithlongcovid19symptomsandendothelialdysfunctiontheresultsoftunendcovstudy |